The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

How to navigate early clinical development and support robust registrational strategy and late-stage development in oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The clinical development strategy in oncology during the last decade has been substantially affected in several ways by the advent of immunotherapy1, and more recently, cell and gene therapy2 treatment options. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Tanja Obradovic, PhD
Vice president, Scientific Affairs, Medical Affairs Oncology, ICON Biotech
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

Patients with metastatic colorectal cancer harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies Braftovi(encorafenib) and Erbitux(cetuximab) plus a mFOLFOX6 chemotherapy regimen, according to results from the phase III BREAKWATER trial led by researchers at the University of Texas MD Anderson Cancer Center.
Clinical Roundup

In HER2+ CRC, anti-HER2 therapy may be less toxic alternative to EGFR inhibitors, phase II study finds

A phase II trial found that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy. Exploratory analysis suggests greater HER2 amplification in a tumor may be associated with greater clinical benefit of dual HER2 inhibitor vs EGFR inhibitor therapy.
Clinical Roundup

SWOG study: Statistical tool provides more accurate estimates of recurrence risk and chemotherapy benefit in breast cancer

A new statistical tool that combines multiple clinical and pathologic factors with a patient’s 21-gene Oncotype DX Breast Recurrence Score result provides more accurate estimates about that patient’s breast cancer prognosis and their potential benefit from chemotherapy than either the Recurrence Score result or clinical factors alone, a SWOG Cancer Research study found.
Byline
Tanja Obradovic, PhD
Vice president, Scientific Affairs, Medical Affairs Oncology, ICON Biotech
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account